Beam Therapeutics (NASDAQ: BEAM) has announced that it will be unveiling its third quarter financial results on Tuesday 5th November 2024. This announcement is set to occur before market open, allowing investors and analysts to gain valuable insights into the company's performance during the quarter.
Wall Street financial analysts are foreseeing that the firm is likely to announce an estimated per share $1.16 loss for the quarter. Furthermore, it is anticipated that the company will disclose a total revenue of $14.5 million during the quarter.
Wall Street analysts have shared their forecasts for the company's annual performance, predicting a total revenue of $48.81 million. Additionally, they expect the company to post loss of $4.67 per share for the fiscal year.
The company's earnings report for the corresponding quarter of the previous year showcased a per-share loss of $1.22. This figure was a result of the company's total revenue, which reached an impressive $17.19 million during that specific period.
The business has scheduled a conference call on 5th November 2024 at 08:30 AM eastern time to discuss Q3 financial results.
Beam Therapeutics (BEAM) closed Friday's regular trading session at $22.93, showing a 4.66 percent gain, with a volume of 777.40 thousand shares.
